首次产前检查时采用快速诊断检测筛查并联用双氢青蒿素-哌喹治疗以实施磺胺多辛-乙胺嘧啶间歇性 presumptive 治疗的 safety 与 efficacy(IPTp-SP+):一项随机对照试验的研究方案
世界卫生组织推荐在高负担地区使用磺胺多辛-乙胺嘧啶间歇性预防治疗孕期疟疾,但随着寄生虫耐药性增加其疗效下降。本方案为一项IIIb期开放标签、两臂随机对照优效性试验,评估在首次产前检查时联合快速诊断检测筛查与双氢青蒿素-哌喹治疗(IPTp-SP+)对比标准IPTp-SP的安全性及疗效,主要终点为第42天PCR确诊的孕期疟疾发病。
要点
- WHO推荐磺胺多辛-乙胺嘧啶间歇性预防治疗用于高负担地区孕期疟疾预防。
- 本研究评估首次产前检查时筛查加双氢青蒿素-哌喹治疗联合标准IPTp-SP的混合方案。
- 主要终点为第42天PCR确诊的孕期疟疾发病。
核心结论
- 研究假设在磺胺多辛-乙胺嘧啶耐药寄生虫流行的高疟疾传播地区,首次就诊时联合筛查与青蒿素联合治疗加标准IPTp-SP的混合方案较单用IPTp-SP具有额外获益。
研究设计与样本
- IIIb期开放标签、两臂随机对照优效性试验方案。
- 纳入无HIV感染且无疟疾体征或症状的孕妇,随机分配至标准IPTp-SP组或IPTp-SP+组。
- IPTp-SP+组中快速诊断检测恶性质疟原虫阳性者首次产前检查时接受双氢青蒿素-哌喹治疗,阴性者按现行指南接受磺胺多辛-乙胺嘧啶。
- 所有参与者在第35天和第63天接受磺胺多辛-乙胺嘧啶,第63天前每两周主动随访,之后每月随访至分娩,婴儿随访至分娩后1年。
主要发现
- 主要终点为第42天PCR确诊的孕期疟疾发病。
- 次要终点包括其他时间点的孕期疟疾发病、胎盘疟疾、先天性疟疾、血红蛋白趋势、出生结局及婴儿至首次生日的不良事件发生率。
局限性
- 试验注册为回顾性注册,于2019年5月11日登记。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended by the World Health Organization for the prevention of malaria in pregnancy (MIP)-associated adverse outcomes in high burden areas. However, the efficacy of IPTp-SP has decreased in step with increasing parasite drug resistance. Suitable alternative strategies are needed. METHODS: This is a protocol for a phase IIIb open-label, two-armed randomized controlled superiority trial to assess the safety and efficacy of a hybrid approach to IPTp combining screening and treatment with dihydroartemisinin-piperaquine (DP) to the current IPTp-SP regimen at the first antenatal care clinic visit. Pregnant women without HIV infection and without signs or symptoms of malaria will be randomized to either standard IPTp-SP or hybrid IPTp-SP plus screening and treatment (IPTp-SP+). In the IPTp-SP+ arm, participants who screen positive by rapid diagnostic test for P. falciparum will be treated with DP at the first antenatal visit while those who screen negative will receive SP per current guidelines. All participants will be administered SP on days 35 and 63 and will be actively followed biweekly up to day 63 and then monthly until delivery. Infants will be followed until 1 year after delivery. The primary endpoint is incident PCR-confirmed MIP at day 42. Secondary endpoints include incident MIP at other time points, placental malaria, congenital malaria, hemoglobin trends, birth outcomes, and incidence of adverse events in infants up to the first birthday. DISCUSSION: A hybrid approach to IPTp that combines screening and treatment with an artemisinin-based combination therapy at the first visit with standard IPTp-SP is hypothesized to confer added benefit over IPTp-SP alone in a high malaria transmission area with prevalent SP resistant parasites. TRIAL REGISTRATION: Pan African Clinical Trials Registry 201905721140808 . Registered retrospectively on 11 May 2019.
引用
- Kabuya JB, Ippolito MM, Sikalima J, et al. Safety and efficacy of intermittent presumptive treatment with sulfadoxine-pyrimethamine using rapid diagnostic test screening and treatment with dihydroartemisinin-piperaquine at the first antenatal care visit (IPTp-SP+): study protocol for a randomized controlled trial. Trials. 2021. PMID: 34801059. doi:10.1186/s13063-021-05745-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。